337 related articles for article (PubMed ID: 15082596)
61. Will non-invasive markers replace liver biopsy for diagnosing and staging fibrosis in non-alcoholic steatohepatitis?
Hashimoto E; Farrell GC
J Gastroenterol Hepatol; 2009 Apr; 24(4):501-3. PubMed ID: 19368628
[No Abstract] [Full Text] [Related]
62. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
Verma S; Jensen D; Hart J; Mohanty SR
Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
[TBL] [Abstract][Full Text] [Related]
63. [Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis].
Heebøll S; Kazankov K; Poulsen MK; Vilstrup H; Grønbæk H
Ugeskr Laeger; 2012 Feb; 174(8):488-90. PubMed ID: 22348670
[TBL] [Abstract][Full Text] [Related]
64. Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis.
Rosso C; Caviglia GP; Abate ML; Vanni E; Mezzabotta L; Touscoz GA; Olivero A; Marengo A; Rizzetto M; Bugianesi E; Smedile A
Dig Liver Dis; 2016 Jan; 48(1):55-61. PubMed ID: 26514735
[TBL] [Abstract][Full Text] [Related]
65. Alkaline phosphatase: can it be considered as an indicator of liver fibrosis in non-alcoholic steatohepatitis with type 2 diabetes?
Kocabay G; Telci A; Tutuncu Y; Tiryaki B; Ozel S; Cevikbas U; Okten A; Satman I
Bratisl Lek Listy; 2011; 112(11):626-9. PubMed ID: 22180989
[TBL] [Abstract][Full Text] [Related]
66. Epidemiology, disease burden and outcomes of cirrhosis in a large secondary care hospital in South Auckland, New Zealand.
Hsiang JC; Bai WW; Raos Z; Stableforth W; Upton A; Selvaratnam S; Gane EJ; Gerred SJ
Intern Med J; 2015 Feb; 45(2):160-9. PubMed ID: 25371019
[TBL] [Abstract][Full Text] [Related]
67. [Gonad function in men with alcoholic liver disease].
Bell H; Frey H; Haug E; Raknerud N
Tidsskr Nor Laegeforen; 1990 Apr; 110(11):1361-5. PubMed ID: 2339380
[TBL] [Abstract][Full Text] [Related]
68. Non-alcoholic fatty liver disease--a common and benign finding in octogenarian patients.
Kagansky N; Levy S; Keter D; Rimon E; Taiba Z; Fridman Z; Berger D; Knobler H; Malnick S
Liver Int; 2004 Dec; 24(6):588-94. PubMed ID: 15566509
[TBL] [Abstract][Full Text] [Related]
69. [Clinical and histological features of non-alcoholic fatty liver disease].
Shi JP; Xun YH; Hu CB; Zhang L; Liu H; Lou GQ; Fan JG
Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):812-6. PubMed ID: 19958638
[TBL] [Abstract][Full Text] [Related]
70. Relationships between fibrosis amounts assessed by morphometry and liver stiffness measurements in chronic hepatitis or steatohepatitis.
Ziol M; Kettaneh A; Ganne-Carrié N; Barget N; Tengher-Barna I; Beaugrand M
Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1261-8. PubMed ID: 19478678
[TBL] [Abstract][Full Text] [Related]
71. Carnitine metabolism in chronic liver disease.
Krähenbühl S
Life Sci; 1996; 59(19):1579-99. PubMed ID: 8913324
[TBL] [Abstract][Full Text] [Related]
72. A prospective study of alcoholic liver disease and mortality.
Bouchier IA; Hislop WS; Prescott RJ
J Hepatol; 1992 Nov; 16(3):290-7. PubMed ID: 1487605
[TBL] [Abstract][Full Text] [Related]
73. Developmental Morphogens & Recovery from Alcoholic Liver Disease.
Diehl AM
Adv Exp Med Biol; 2018; 1032():145-151. PubMed ID: 30362097
[TBL] [Abstract][Full Text] [Related]
74. [The incidence of palmar erythema in patients with alcoholic fatty liver--a comparative study with fatty liver of other origins].
Tarao K; Sakurai A; Hayashi K; Chin E; Ikeda T; Ito T; Iida Y; Shiokawa A
Nihon Shokakibyo Gakkai Zasshi; 1986 Nov; 83(11):2365-74. PubMed ID: 3820761
[No Abstract] [Full Text] [Related]
75. Fatty liver and sudden death. A review.
Randall B
Hum Pathol; 1980 Mar; 11(2):147-53. PubMed ID: 6105125
[TBL] [Abstract][Full Text] [Related]
76. Pure alcoholic fatty liver and progression to cirrhosis or fibrosis.
Ho AM; Contardi LH
Lancet; 1995 Dec; 346(8989):1562-3. PubMed ID: 7491074
[No Abstract] [Full Text] [Related]
77. Dyslipidemia and non-alcoholic fatty liver disease.
Manickam P; Sudhakar R
Dig Dis Sci; 2013 May; 58(5):1435. PubMed ID: 23508978
[No Abstract] [Full Text] [Related]
78. One liver, two samples and two diagnoses-An example of how multiple samples by laparoscopically guided liver biopsy can be decisive.
Beisel C; Weidemann SA; Sebode M
Liver Int; 2021 Nov; 41(11):2786-2787. PubMed ID: 34587344
[No Abstract] [Full Text] [Related]
79. Analysis of the correlation between non-alcoholic fatty liver disease and bone metabolism indicators in healthy middle-aged men.
Pontillo G; Macaro D; Monaco L
Eur Rev Med Pharmacol Sci; 2018 Apr; 22(8):2187-2188. PubMed ID: 29762816
[No Abstract] [Full Text] [Related]
80. Frontiers in fatty liver: recent advances in pathogenic mechanisms, assessment of patients' prognosis and pharmacotherapy : MASLD: new pathogenic mechanisms, risk assessment tools and drug therapies.
Fernández-Barrena MG; Avila MA
J Physiol Biochem; 2023 Nov; 79(4):811-813. PubMed ID: 37864126
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
